Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| British Columbia Cancer Agency | OTHER |
Not provided
Not provided
Not provided
Not provided
This study will explore the feasibility (suitability), efficacy (research-setting outcomes), and participant satisfaction of a virtually-supervised 12-week exercise and diet intervention for women with ovarian cancer. It will include exercise, behavior change strategies, and guidance around healthy eating. Participants will be instructed and supervised virtually in two exercise sessions weekly for 12 weeks by a professional trained to deliver the program. An additional 1 exercise session per week, completed independently, will be added from weeks 4-12 of the program. Finally participants will participate in two separate virtual group nutrition sessions. Assessments will occur at baseline, end-of-intervention, and 6 months post-baseline.
Purpose: To assess the feasibility, preliminary efficacy, and patient perspectives of a 12-week supervised, virtually-delivered exercise and healthy eating program for women living with and beyond ovarian cancer.
Hypothesis: The investigators hypothesize that the program will be feasible and will demonstrate efficacy, and that patient perspectives will be overall positive and in support of the program.
Justification: Women living with and beyond ovarian cancer exercise at levels below the general population, and are at an increased risk for falls. Exercise and healthy eating programming is not a part of routine care. This project has the potential to demonstrate a feasible and relatively low-cost option for offering such programming.
Objectives: the objectives of this program are: 1) Primary Objective: To measure the feasibility of delivering the BE-BALANCED program from a virtual (i.e. live video) setting. Feasibility will be evaluated per individual item based on a priori targets; 2) Secondary Objective: To evaluate the preliminary efficacy of the BE-BALANCED program; 3) Tertiary Objective: To evaluate patient satisfaction (post-intervention only)
Research Design: This study is a prospective single-arm feasibility study.
Statistical Analysis: The primary aim is feasibility. This will be evaluated using descriptive statistics, focusing on the program recruitment, attendance, attrition, and fidelity. For secondary and tertiary/exploratory aims, a repeated measures ANOVA will be performed for each measure to evaluate the change in outcomes from baseline and end of intervention (12-weeks) and 3-month follow-up. In addition to the RM-ANOVA, an effect size for each measure will be calculated based on the same time-frame comparisons. SPSS will be used to process data.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Arm | Experimental | This is a single arm pilot study of group base exercise |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Be-Balanced | Behavioral | The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline). |
| Measure | Description | Time Frame |
|---|---|---|
| Accrual | Assessed by meeting accrual targets (number recruited) | Baseline (0 weeks) |
| Intervention Adherence | Assessed as number of supervised virtual sessions that a participant attended, out of a total of 24 group exercise sessions, and number of self-directed sessions completed, out of a total of 9 sessions. | Baseline to 12 weeks |
| Attrition | Assessed as number of drop-outs during the 12-week program. | Baseline to 12 weeks |
| Fidelity of group belonging | Group Belonging Scale (0-20; higher is better) | Baseline to 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Physical function: Gait speed | Measured by the gait speed portion of The Short Physical Performance Battery. Measured in seconds. | Change from baseline to 12 weeks (end of intervention) |
| Physical function: Functional mobility |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate patient satisfaction | Overall satisfaction; measured on scale 0-7 with higher score meaning higher satisfaction. | Baseline to 12 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kelly Mackenzie | Contact | 2508972609 | kelly.mackenzie@ubc.ca |
| Name | Affiliation | Role |
|---|---|---|
| Kristin L Campbell | Department of Physical Therapy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Exercise Physiology Lab | Vancouver | British Columbia | V6T 1Z3 | Canada |
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
Not provided
Not provided
Prospective single-arm feasibility study
Not provided
Not provided
Not provided
Not provided
|
Measured by 8 foot timed up and go (Seniors Fitness Test). Measured by distance in seconds.
| Change from baseline to 12 weeks (end of intervention) |
| Physical function: Lower extremity strength and endurance | Measured by 30-second chair stand (Seniors Fitness Test). Measured in repetitions completed. | Change from baseline to 12 weeks (end of intervention) |
| Physical function: Upper extremity strength and endurance | Measured by 30-second biceps curl (Seniors Fitness Test). Measured in repetitions completed. | Change from baseline to 12 weeks (end of intervention) |
| Physical function: Balance | Measured by Functional Reach Test. Measured in centimeters. | Change from baseline to 12 weeks (end of intervention) |
| Cardiovascular Fitness | Measured by the Six Minute Walk test. Measured in meters. | Change from baseline to 12 weeks (end of intervention) |
| Height | Measured using stadiometer. Measured in meters | Change from baseline to 12 weeks (end of intervention) |
| Weight | Measured using a scale. Measured in kilograms | Change from baseline to 12 weeks (end of intervention) |
| Body mass index | Aggregated measure of height and weight, reported in kilograms/meter^2 | Change from baseline to 12 weeks (end of intervention) |
| Waist circumference | Measured in centimeters | Change from baseline to 12 weeks (end of intervention) |
| Hip circumference | Measured in centimeters | Change from baseline to 12 weeks (end of intervention) |
| Health-related quality of life: Physical Health | Measured by 36-item Short Form Health Survey; Norm-based 0-100, higher score represents better health | Change from baseline to 12 weeks (end of intervention) |
| Health-related quality of life: Mental Health | Measured by 36-item Short Form Health Survey; Norm-based 0-100, higher score represents better health | Change from baseline to 12 weeks (end of intervention) |
| Depression and anxiety | Measured by Hospital Anxiety and Depression Scale; Score range 0-21, higher score is higher depression and anxiety. | Change from baseline to 12 weeks (end of intervention) |
| Usual physical activity levels | Measured by Modified Godin Leisure Time Physical Activity questionnaire; Scoring range 0 - no specified maximum. Scoring < 14 units "insufficiently Active" ; 14-23 is "moderately active" and >=24 is "active". | Change from baseline to 12 weeks (end of intervention) |
| Falls | Measured by standard falls calendar for the duration of the study as number of falls. | Change from baseline to 12 weeks (end of intervention) |
| D005831 |
| Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |